Toyoma’s Rheumatoid Arthritis Drug T-5224 Enters Phase II
This article was originally published in PharmAsia News
Executive Summary
Toyoma Chemical's rheumatoid arthritis drug T-5224 enters Phase II clinical trials. The low-polymer compound concluded Phase I trials in June 2006; results indicated the compound may prevent breakdown in joints and bones. Toyama signed a research, development and marketing license with Hoffman La Roche Ltd. (Click for more - Japanese language)